VYGR · Voyager Therapeutics

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

75 Hayden Avenue, Lexington, MA, 02421, United States
Biotechnology
Healthcare

Market Cap

101.4M

52 Wk Range

$1.59 - $5.48

Previous Close

$1.73

Open

$1.70

Volume

567,102

Day Range

$1.62 - $1.74

Enterprise Value

31.36M

Cash

106.8M

Avg Qtr Burn

-19.67M

Insider Ownership

14.81%

Institutional Own.

58.83%

Qtr Updated

Sep 30th 2026